Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial.

Journal of medical virology - 1 Dec 2021

Abbass Sherif, Kamal Ehab, Salama Mohsen, Salman Tary, Sabry Alyaa, Abdel-Razek Wael, Helmy Sherine, Abdelgwad Ahmed, Sakr Neamt, Elgazzar Mohamed, Einar Mohamed, Farouk Mahmoud, Saif Mounir, Shehab Ismail, El-Hosieny Eman, Mansour Mai, Mahdi Doaa, Tharwa El-Sayed, Salah Mostafa, Elrouby Ola, Waked Imam

Abstract excerpt

Only a few treatments are approved for coronavirus disease-2019 (COVID-19) infections, with continuous debate about their clinical impact. Repurposing antiviral treatments might prove the fastest way to identify effective therapy. This trial aimed to evaluate the efficacy and safety of sofosbuvir (SOF) plus daclatasvir (DCV) or ravidasvir (RDV) added to standard care (SOC) for patients with moderate and severe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carbamates

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Imidazoles

Share to Intensive Care Units

Share to Pyrrolidines

Share to Sofosbuvir

Share to Valine

Source

Open in PubMed Open full text

Identifiers

PMID: 34379337
DOI: 10.1002/jmv.27264
PMCID: PMC8426808

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial.PMID 34379337Read ↗

Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials.Semantic proximity Read ↗

Evaluation of the Effect of Sofosbuvir and Daclatasvir in Hospitalised COVID-19 Patients: A Randomized Double-Blind Clinical Trial (DISCOVER)Semantic proximity Read ↗

Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.Semantic proximity Read ↗

Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.Semantic proximity Read ↗

The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trialsSemantic proximity Read ↗

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir Vs Currently Used Therapy in Severe COVID-19 Adults. (COMVIVIR, clinicaltrials.gov NCT04475991)Semantic proximity Read ↗

REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity Read ↗

Efficiency of antiviral treatment in COVID‑19Semantic proximity Read ↗

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial.Semantic proximity Read ↗

Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.Semantic proximity Read ↗

Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.Semantic proximity Read ↗

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.